Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
AssigneeTeijin Pharma Limited
InventorsHiroshi Eguchi, Akira Tanokura, Kenichiro Takagi, Hirotsugu Kato, Satoshi Yamamura, Naoko Namiki
Life of this patent
Estimating the term…
Abstract
The present invention provides an anti-IGF-I receptor antibody that binds specifically to an IGF-I receptor of a vertebrate and has the proliferation-inducing activity of a vertebrate-derived cell, or a fragment thereof, or derivatives of these.
Claims44
An anti-IGF-I (Insulin-like Growth Factor I) receptor antibody or antigen-binding fragment thereof that exhibits an activity to induce growth of vertebrate-derived cells,
- wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising three complementarity-determining regions (CDRs H1-H3), and further comprises a light chain variable region comprising three complementarity-determining regions (CDRs L1-L3),
- wherein the CDR-H1 comprises the amino acid sequence of SEQ ID NO:
- 3, or comprises the amino acid sequence of SEQ ID NO:
- 3 in which one amino acid is substituted, deleted, or inserted;
- wherein the CDR-H2 comprises the amino acid sequence of SEQ ID NO:
- 4, or comprises the amino acid sequence of SEQ ID NO:
- 4 in which up to two amino acids are substituted, deleted, or inserted;
- wherein the CDR-H3 comprises the amino acid sequence of SEQ ID NO:
- 5, or comprises the amino acid sequence of SEQ ID NO:
- 5 in which up to two amino acids are substituted, deleted, or inserted;
- wherein the CDR-L1 comprises the amino acid sequence of SEQ ID NO:
- 6, or comprises the amino acid sequence of SEQ ID NO:
- 6 in which up to two amino acids are substituted, deleted, or inserted;
- wherein the CDR-L2 comprises the amino acid sequence of SEQ ID NO:
- 7, or comprises the amino acid sequence of SEQ ID NO:
- 7 in which one amino acid is substituted, deleted, or inserted;
- wherein the CDR-L3 comprises the amino acid sequence of SEQ ID NO:
- 8, or comprises the amino acid sequence of SEQ ID NO:
- 8 in which up to two amino acids are substituted, deleted, or inserted.
The anti-IGF-I receptor antibody or antigen-binding fragment thereof according to claim which does not change the blood glucose level of a vertebrate when parenterally administered to the vertebrate at a dosage of 10 times or more of an effective dosage sufficient to induce an increase in the muscle mass and/or the body length of the vertebrate.
An anti-IGF-I receptor antibody or antigen-binding fragment thereof that exhibits an activity to induce growth of vertebrate-derived cells, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence at least 90% identical to the entirety of the amino acid sequence of SEQ ID NO:
- 9;
- and
- wherein said antibody or antigen-binding fragment thereof further comprises a light chain variable region comprising an amino acid sequence at least 90% identical to the entirety of the amino acid sequence of SEQ ID NO:
- 10.
Dependencies are inferred from the claim text.